Tes Pharma Presents Results on TESP-0401 in a Model of Kidney Transplantation at the 31st International Congress of the Transplantation Society

Tes Pharma Presents Results on TESP-0401 in a Model of Kidney Transplantation at the 31st International Congress of the Transplantation Society Solomeo-Corciano (PG), Italy, September 17, 2026 – Tes Pharma, a biopharmaceutical company focused on developing first-in-class therapeutics for high unmet medical needs in renal diseases, announced today the presentation of new preclinical data on its clinical candidate TESP-0401 at the 31st International Congress of the Transplantation Society in Sydney, Australia. The study shows that pharmacological inhibition of ACMSD with TESP-0401 confers significant tissue protection and renal functional improvements by reducing delayed graft function (DGF) in a clinically relevant mouse model of kidney transplantation. “These findings provide the first preclinical evidence that TESP-0401 can protect the transplanted kidney during the critical early period after surgery.” said Andrea Pellacani, Chief Medical Officer at Tes Pharma . “In a model characterized by prolonged cold ischemia, TESP-0401 preserved renal function and markedly reduced tubular injury. These results further support ACMSD inhibition and restoration of de novo NAD ⁺ biosynthesis as an effective strategy to address delayed graft function after kidney transplantation”. Title: TESP-0401 improves delayed graft function in a kidney transplantation mouse model Session: #283: Insights into old and new therapeutics 1 Room: C3.4 - C3.5 Date and time: Monday, September 21, 2026, at 3:30 PM by Nicola Giacchè, PhD, Tes Pharma About TESP-0401 TESP‑0401 is a first‑in‑class ACMSD inhibitor that restores NAD⁺ levels by enhancing its de novo biosynthesis. Dysregulation of this pathway, and the resulting decline in NAD⁺ levels, are key drivers of mitochondrial dysfunction and cellular energy failure across multiple indications, including acute (AKI) and chronic kidney diseases (CKD), as well as metabolic disorders. By inhibiting ACMSD, selectively and highly expressed in tubular epithelial cells, TESP‑0401 restores NAD⁺ levels in the kidney, thereby supporting mitochondrial function and cellular energetics. This mechanism targets a fundamental driver of disease progression, enabling recovery of essential cellular processes and improving cellular homeostasis under conditions of stress and injury. Importantly, TESP‑0401 not only confers protection in AKI but also extends its therapeutic potential to CKD, where mitochondrial dysfunction and tubular injury contribute to progressive loss of renal function and fibrosis. By targeting NAD⁺ metabolism, TESP‑0401 represents a novel and differentiated approach to prevent tubular damage, reduce fibrosis, and preserve kidney function in renal diseases. Delayed Graft Function (DGF) DGF is a major unmet need in kidney transplantation. DGF, generally defined as the requirement for dialysis within seven days after transplantation, reflects acute injury to the transplanted kidney. The condition affects a substantial proportion of deceased-donor kidney transplant recipients and is associated with worse clinical outcomes, including longer hospital stays, increased risk of rejection, reduced graft performance, and lower long-term graft survival. Despite its clinical and economic burden, no pharmacological therapy has been approved specifically for the prevention of DGF, creating a significant opportunity for innovative therapeutic approaches aimed at improving early graft recovery and long-term transplant outcomes. About Tes Pharma Tes Pharma, a biopharmaceutical company focused on developing first-in-class therapeutics for high unmet medical needs in renal diseases. The company’s lead compound TESP-0401 demonstrated significant effect in models of acute (AKI) and chronic kidney diseases (CKD). TESP-0401 is undergoing first-in human SAD/MAD studies. Tes Pharma pipeline includes a series of compounds for CKD and renal fibrosis in different stages of preclinical development. For more information, please visit www.tespharma.com or connect with the Company on LinkedIn For further information, please contact: Sara Malincarne [email protected] www.tespharma.com Link to PDF

The release as fetched from its publisher. tespharma.com ↗